Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapy

Circulation: Cardiovascular Genetics

Volumn 5, Issue 6, 2012, Pages 676-685

  Chu, Audrey Y ^a   Guilianini, Franco ^a   Grallert, Harald ^b   Dupuis, Josée ^c,d   Ballantyne, Christie M ^e   Barratt, Bryan J ^f   Nyberg, Fredrik ^g,h   Chasman, Daniel I ^a,i   Ridker, Paul M ^a,i  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c FRAMINGHAM HEART STUDY   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e Methodist DeBakey Heart and Vascular Center   (United States)

^f ASTRAZENECA   (United Kingdom)

^g ASTRAZENECA R AND D   (Sweden)

^h UNIVERSITY OF GOTHENBURG   (Sweden)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Epidemiology; Genetics; Genome wide association study; Lipoprotein associated phospholipase A2; Meta analysis; Statin therapy

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN C1; APOLIPOPROTEIN E; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL;

ARTICLE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; GENE LOCUS; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; FEMALE; FLUOROBENZENES; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; META-ANALYSIS AS TOPIC; MOLECULAR WEIGHT; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIMIDINES; REPRODUCIBILITY OF RESULTS; SULFONAMIDES;

EID: 84873919548     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.112.963314     Document Type: Article

References (34)

1. Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, et al; Lp-PLA(2) Studies Collaboration. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: Collaborative analysis of 32 prospective studies. Lancet. 2010;375:1536-1544.
2. Häkkinen T, Luoma JS, Hiltunen MO, Macphee CH, Milliner KJ, Patel L, et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1999;19:2909-2917.
3. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:2523-2529.
4. Wilensky RL, Shi Y, Mohler ER 3rd, Hamamdzic D, Burgert ME, Li J, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med. 2008;14:1059-1066.
5. Jang Y, Waterworth D, Lee JE, Song K, Kim S, Kim HS, et al. Carriage of the V279F null allele within the gene encoding Lp-PLA is protective from coronary artery disease in South Korean males. PLoS ONE. 2011;6:e18208.
6. Hou L, Chen S, Yu H, Lu X, Chen J, Wang L, et al. Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: The Beijing atherosclerosis study. Hum Genet. 2009;125:11-20.
7. Wang Q, Hao Y, Mo X, Wang L, Lu X, Huang J, et al. PLA2G7 gene polymorphisms and coronary heart disease risk: A meta-analysis. Thromb Res. 2010;126:498-503.
8. Casas JP, Ninio E, Panayiotou A, Palmen J, Cooper JA, Ricketts SL, et al. PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. Circulation. 2010;121:2284-2293.
9. Schnabel R, Dupuis J, Larson MG, Lunetta KL, Robins SJ, Zhu Y, et al. Clinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study. Atherosclerosis. 2009;204:601-607.
10. Guerra R, Zhao B, Mooser V, Stafforini D, Johnston JM, Cohen JC. Determinants of plasma platelet-activating factor acetylhydrolase: Heritability and relationship to plasma lipoproteins. J Lipid Res. 1997;38:2281-2288.
11. Lenzini L, Antezza K, Caroccia B, Wolfert RL, Szczech R, Cesari M, et al. A twin study of heritability of plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity. Atherosclerosis. 2009;205:181-185.
12. Ninio E, Tregouet D, Carrier JL, Stengel D, Bickel C, Perret C, et al. Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Hum Mol Genet. 2004;13:1341-1351.
13. Hoffmann MM, Winkler K, Renner W, Winkelmann BR, Seelhorst U, Wellnitz B, et al. Genetic variants and haplotypes of lipoprotein associated phospholipase A2 and their influence on cardiovascular disease (The Ludwigshafen Risk and Cardiovascular Health Study). J Thromb Haemost. 2009;7:41-48.
14. Suchindran S, Rivedal D, Guyton JR, Milledge T, Gao X, Benjamin A, et al. Genome-wide association study of Lp-PLA(2) activity and mass in the Framingham Heart Study. PLoS Genet. 2010;6:e1000928.
15. Grallert H, Dupuis J, Bis JC, Dehghan A, Barbalic M, Baumert J, et al. Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: Meta-analysis of genome-wide association studies from five community-based studies. Eur Heart J. 2012;33:238-251.
16. The stabilization of atherosclerotic plaque by initation of darapladib therapy trial (STABILITY). http://clinicaltrials.gov/ct2/show/nct00799903, Accessed August 24, 2012.
17. The stabilization of plaques using darapladib-thromboysis in myocardial infarction 52 Trial (SOLID-TIMI). http://clinicaltrials.gov/ct2/show/ NCT01000727. Accessed August 24, 2012.
18. Albert MA, Glynn RJ, Wolfert RL, Ridker PM. The effect of statin therapy on lipoprotein associated phospholipase A2 levels. Atherosclerosis. 2005;182:193-198.
19. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
20. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559-575.
21. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006;38:904-909.
22. Barber MJ, Mangravite LM, Hyde CL, Chasman DI, Smith JD, McCarty CA, et al. Genome-wide association of lipid-lowering response to statins in combined study populations. PLoS ONE. 2010;5:e9763.
23. Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet. 2012;5:257-264.
24. Willer CJ, Li Y, Abecasis GR. METAL: Fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26:2190-2191.
25. Mallat Z, Lambeau G, Tedgui A. Lipoprotein-associated and secreted phospholipases A in cardiovascular disease: Roles as biological effectors and biomarkers. Circulation. 2010;122:2183-2200.
26. McConnell JP, Jaffe AS. Variability of lipoprotein-associated phospholipase A2 measurements. Clin Chem. 2008;54:932-933.
27. Stein EA. Lipoprotein-associated phospholipase A measurements: Mass, activity, but little productivity. Clin Chem. 2012;58:814-817.
28. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466:707-713.
29. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al Alzheimer's Disease Neuroimaging Initiative; CHARGE consortium; EADI1 consortium. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43:429-435.
30. Dusetti NJ, Jiang Y, Vaccaro MI, Tomasini R, Azizi Samir A, Calvo EL, et al. Cloning and expression of the rat vacuole membrane protein 1 (VMP1), a new gene activated in pancreas with acute pancreatitis, which promotes vacuole formation. Biochem Biophys Res Commun. 2002;290:641-649.
31. Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008;36:2014-2023.
32. Chasman DI, Shiffman D, Zee RY, Louie JZ, Luke MM, Rowland CM, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis. 2009;203:371-376.
33. Blencowe C, Hermetter A, Kostner GM, Deigner HP. Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein(a) in comparison with low density lipoprotein. J Biol Chem. 1995;270:31151-31157.
34. Tselepis AD, John Chapman M. Inflammation, bioactive lipids and atherosclerosis: Potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl. 2002;3:57-68.